Dr Reddy’s receives EUA for Sputnik V in India
Sputnik V uses two different vectors for the two shots in a course of vaccination and its efficacy was determined to be 91.6 per cent as per a published article in the Lancet
Dr Reddy’s Laboratories announced that it has received permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act.
In September 2020, Dr Reddy’s had partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and distribute the vaccine in India. In addition to the trials conducted in Russia by RDIF. Phase II/III clinical trials of the vaccine were carried out by Dr Reddy’s in India.
GV Prasad, Co-chairman and MD, Dr Reddy’s Laboratories said, “We are very pleased to obtain the emergency use authorisation for Sputnik V in India. With the rising cases in India, vaccination is the most effective tool in our battle against COVID-19. This will enable us to contribute to our nation’s effort of vaccinating a significant proportion of our population.”
Sputnik V is now approved for use in 60 countries around the world. Sputnik V uses two different vectors for the two shots in a course of vaccination. The efficacy of Sputnik V was determined to be 91.6 per cent as per a published article in the Lancet.
- Advertisement -